Faulkner M A, Wadibia E C, Lucas B D, Hilleman D E
Department of Pharmacy Practice, Creighton University School of Pharmacy and Allied Health Professions, Omaha, Nebraska 68178, USA.
Pharmacotherapy. 2000 Apr;20(4):410-6. doi: 10.1592/phco.20.5.410.35048.
This randomized, controlled trial evaluated the impact of personalized follow-up on compliance rates in high-risk patients receiving combination lipid-lowering therapy over 2 years. A random sample of 30 patients 7-30 days after cardiac surgery had baseline fasting low-density lipoprotein levels higher than 130 mg/dl. All patients received lovastatin 20 mg/day and colestipol 5 g twice/day. Weekly telephone contact was made with each patient for 12 weeks. Short- and long-term compliance was assessed by pill and packet counts and refill records. Compliance and lipid profile results were significantly better in the intervention group (p<0.05) up to 2 years after the start of therapy than in the control group for all parameters except high-density lipoprotein. However, this effect was not apparent during the first 12 weeks of therapy. Short-term telephone follow-up favorably affected compliance and lipid profile results up to 2 years after start of therapy.
这项随机对照试验评估了个性化随访对接受联合降脂治疗两年的高危患者依从率的影响。对心脏手术后7至30天的30名患者进行随机抽样，其基线空腹低密度脂蛋白水平高于130mg/dl。所有患者均接受洛伐他汀20mg/天和考来烯胺5g，每日两次。每周与每位患者进行电话联系，持续12周。通过药片计数、包装计数和再填充记录评估短期和长期依从性。在治疗开始后长达2年的时间里，干预组的依从性和血脂谱结果在除高密度脂蛋白外的所有参数上均显著优于对照组（p<0.05）。然而，在治疗的前12周内这种效果并不明显。短期电话随访对治疗开始后长达2年的依从性和血脂谱结果产生了有利影响。
